Atara Biotherapeutics Inc. (ATRA) shares rocketed 19.28% in after-hours on Monday, December 13, 2021, and closed the daily trading at $18.68. However, in the regular trading session on Monday, ATRA’s stock lost 2.00%. ATRA shares have fallen 35.07% over the last 12 months, and they have moved down 7.77% in the past week.
Let’s have a brief look at its recent news and developments.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
ATRA Pivotal Phase 3 Trial Results of (ALLELE) of Tab-cel®
On December 14, 2021, Atara Biotherapeutics, Inc. (ATRA) presented efficacy and safety results from its Phase 3 multicenter ALLELE study investigating tabelecleucel (tab-cel®) for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) following solid organ transplant (SOT) or hematopoietic cell transplant (HCT) at the 63rd American Society of Hematology (ASH) Annual Meeting.
Safety was consistent with previously published data, and no new safety signals or concerns were reported. The company presented a total of eight abstracts during the meeting.
ATRA presented preliminary results for ATA2271
On December 09, 2021, Atara Biotherapeutics, Inc. (ATRA), announced new preclinical and preliminary clinical results for ATA2271, a next-generation autologous chimeric antigen receptor (CAR) T-cell therapy targeting mesothelin (MSLN). The data was presented by collaborators at Memorial Sloan Kettering Cancer Center as a mini-oral session at the European Society for Medical Oncology Immuno-Oncology (ESMO I‑O) Congress 2021, in Geneva, Switzerland.
ATRA received EU Marketing Authorization for abelecleucel
On November 30, 2021, the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for ATRA tabelecleucel (tab-cel®). Tab-cel is an investigational treatment for patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy following solid organ transplant (SOT) or hematopoietic cell transplant (HCT).
ATRA latest financial results
On November 04, 2021, Atara Biotherapeutics, Inc. (ATRA), released its financial results for the third quarter of 2021.
Q3 2021 financial highlights
- ATRA reported total revenue of $5.4 million for the third quarter of 2021 compared to zero revenue in Q3 2020.
- Total operating expenses were $16.0 million in Q3 2021 compared to $15.4 million in Q3 2020.
- Atara suffered a net loss of $84.7 million, or $0.90 per share, for the third quarter of 2021, as compared to $74.3 million, or $0.92 per share, for the same period in 2020.
- As of September 30, 2021, the company had cash, cash equivalents, and short-term investments totaling $357.2 million compared to $373.4 million as of June 30, 2021.
Well, the recent positive results of the Phase 3 trial of Tab-cel were the reason behind its top-notch performance in the after-hours on Monday and it can continue to climb up in the coming trading sessions on Tuesday.